Literature DB >> 24651583

Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases.

Ashwin N Ananthakrishnan1, Deanna D Nguyen, Jenny Sauk, Vijay Yajnik, Ramnik J Xavier.   

Abstract

BACKGROUND: Cigarette smoking is a well-established environmental risk factor for Crohn's disease (CD) and ulcerative colitis (UC). The exact mechanism of its effect remains unexplained. Genetic polymorphisms in metabolizing enzymes may influence susceptibility to the effect of smoking and shed light on its mechanism of action.
METHODS: We used a prospective cohort of patients with CD, UC, and healthy controls. Smoking status was defined as current, former, or never smoking. Patients were genotyped for polymorphisms in CYP2A6, glutathione transferase enzymes (GSTP1 and GSTM1), NAD(P)H quinone oxidoreductase (NQO), and heme oxygenase 1 using a Sequenom platform. Multivariate logistic regression models with CD or UC as the outcome, stratified by genotype, were developed and interaction P-values calculated.
RESULTS: Our study included 634 patients with CD, 401 with UC, and 337 healthy controls. Ever smokers had an increased risk of CD (odds ratio = 3.88, 95% confidence interval = 2.35-6.39) compared with nonsmokers among patients with AG/AA genotypes at CYP2A6. However, ever smoking was not associated with CD among patients with the AA genotype (Pinteraction = 0.001). Former smoking was associated with an increased risk for UC only in the presence of GG/AG genotypes for GSTP1 but not in those with the AA genotype (Pinteraction = 0.012). Polymorphisms at the NQO and HMOX loci did not demonstrate a statistically significant interaction with smoking and risk of CD or UC.
CONCLUSIONS: Genetic polymorphisms in metabolizing enzymes may influence the association between smoking and CD and UC. Further studies of gene-environment interaction in inflammatory bowel disease are warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24651583      PMCID: PMC4113010          DOI: 10.1097/MIB.0000000000000014

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  42 in total

1.  Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Authors:  V Malaiyandi; C Lerman; N L Benowitz; C Jepson; F Patterson; R F Tyndale
Journal:  Mol Psychiatry       Date:  2006-04       Impact factor: 15.992

Review 2.  Unravelling the pathogenesis of inflammatory bowel disease.

Authors:  R J Xavier; D K Podolsky
Journal:  Nature       Date:  2007-07-26       Impact factor: 49.962

3.  What is the link between the use of tobacco and IBD?

Authors:  Jacques Cosnes
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

4.  Does smoking decrease the response to infliximab in patients with Crohn's disease?

Authors:  Mansour A Parsi
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

5.  Effects of 10 cigarette smoke condensates on primary human airway epithelial cells by comparative gene and cytokine expression studies.

Authors:  Gavin Pickett; Jeanclare Seagrave; Susan Boggs; Gregory Polzin; Patricia Richter; Yohannes Tesfaigzi
Journal:  Toxicol Sci       Date:  2009-12-15       Impact factor: 4.849

Review 6.  Inflammatory bowel disease.

Authors:  Clara Abraham; Judy H Cho
Journal:  N Engl J Med       Date:  2009-11-19       Impact factor: 91.245

7.  Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties.

Authors:  P Zimniak; B Nanduri; S Pikuła; J Bandorowicz-Pikuła; S S Singhal; S K Srivastava; S Awasthi; Y C Awasthi
Journal:  Eur J Biochem       Date:  1994-09-15

8.  Influence of CYP2A6*4 genotypes on maternal serum cotinine among Chinese nonsmoking pregnant women.

Authors:  Chuanbo Xie; Xiaozhong Wen; Peng Ding; Tao Liu; Yanhui He; Zhongzheng Niu; Jianmiao Lin; Shixin Yuan; Xiaoling Guo; Deqin Jia; Weiqing Chen
Journal:  Nicotine Tob Res       Date:  2013-10-25       Impact factor: 4.244

9.  Effects of light smoking consumption on the clinical course of Crohn's disease.

Authors:  Philippe Seksik; Isabelle Nion-Larmurier; Harry Sokol; Laurent Beaugerie; Jacques Cosnes
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

10.  Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

Authors:  Vibeke Andersen; Mette Ostergaard; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2009-11-21       Impact factor: 4.430

View more
  12 in total

Review 1.  Application of computational methods in genetic study of inflammatory bowel disease.

Authors:  Jin Li; Zhi Wei; Hakon Hakonarson
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  Epidemiology and risk factors for IBD.

Authors:  Ashwin N Ananthakrishnan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-03       Impact factor: 46.802

3.  Genetic and environmental factors drive personalized medicine for Crohn's disease.

Authors:  Shigeru Oshima; Mamoru Watanabe
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

Review 4.  Inflammatory bowel disease as a model for translating the microbiome.

Authors:  Curtis Huttenhower; Aleksandar D Kostic; Ramnik J Xavier
Journal:  Immunity       Date:  2014-06-19       Impact factor: 31.745

Review 5.  Environmental Hygiene and Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Authors:  Aurada Cholapranee; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

6.  Role of environmental factors in the pathogenesis of Crohn's disease: a critical review.

Authors:  Yueying Chen; Yining Wang; Jun Shen
Journal:  Int J Colorectal Dis       Date:  2019-11-16       Impact factor: 2.571

7.  Genetic risk factors for serious infections in inflammatory bowel diseases.

Authors:  Saranya Sasidharan; Vijay Yajnik; Hamed Khalili; John Garber; Ramnik Xavier; Ashwin N Ananthakrishnan
Journal:  Scand J Gastroenterol       Date:  2017-02-05       Impact factor: 2.423

8.  Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.

Authors:  P Vedak; D Kroshinsky; J St John; R J Xavier; V Yajnik; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2016-01-24       Impact factor: 8.171

Review 9.  Environmental risk factors for inflammatory bowel diseases: a review.

Authors:  Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2014-09-10       Impact factor: 3.199

Review 10.  Genetics and Pathogenesis of Inflammatory Bowel Disease.

Authors:  Ta-Chiang Liu; Thaddeus S Stappenbeck
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.